Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Strides’ approval for this product marks the 1st Indian approval from the USFDA for this complex formulation
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Subscribe To Our Newsletter & Stay Updated
